FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? October 3, 2023 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors January 28, 2021 Load more HOT NEWS A radical project: video game design meets cancer research FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma Trial Results Highlight Changing Lung Cancer Treatment Landscape Acing it: The ambitious early career researchers driving progress in cancer...
